Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients

Michael Praktiknjo, Natalie Djayadi, Raphael Mohr, Robert Schierwagen, Jenny Bischoff, Leona Dold, Alessandra Pohlmann, Carolynne Schwarze-Zander, Jan Christian Wasmuth, Christoph Boesecke, Jürgen K. Rockstroh, Jonel Trebicka

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Background: Severe hepatic steatosis shows a high prevalence and contributes to morbidity and mortality in human immunodeficiency virus (HIV) infected patients. Known risk factors include obesity, dyslipidaemia and features of metabolic syndrome. Fibroblast growth factor 21 (FGF-21) is involved with hepatic glucose and lipid metabolism. This study aimed to evaluate FGF-21 as a biomarker for severe hepatic steatosis in non-obese HIV-infected patients. Methods: This is a prospective, cross-sectional, monocentric study including HIV-infected out-patients. Hepatic steatosis was measured via controlled attenuation parameter (CAP) using FibroScan 502 touch (ECHOSENS, France). Severe hepatic steatosis was defined at CAP ≥ 253 dB/m. Peripheral blood samples were collected and plasma was analysed for FGF-21. Demographic and clinical characteristics were collected from patient's health records. Results: In total, 73 non-obese HIV-monoinfected patients were included in this study. Prevalence of severe hepatic steatosis was 41%. Patients with severe hepatic steatosis showed significantly higher levels of FGF-21. Univariate analysis revealed FGF-21, BMI, hyperlipidaemia, ALT levels and arterial hypertension as significant, while multivariate analysis showed only FGF-21, arterial hypertension and ALT levels as significant independent risk factors for severe hepatic steatosis. Conclusion: This study presents FGF-21 as an independent and stronger predictor of severe hepatic steatosis than blood lipids in HIV-infected patients. Moreover, arterial hypertension and ALT levels predict severe steatosis even in non-obese HIV-monoinfected patients. Furthermore, this study supports existing metabolic risk factors and expands them to non-obese HIV-infected patients.

OriginalsprogEngelsk
TidsskriftLiver International
Vol/bind39
Udgave nummer8
Sider (fra-til)1514-1520
ISSN1478-3223
DOI
StatusUdgivet - aug. 2019

Fingeraftryk

HIV
Liver
fibroblast growth factor 21
Dyslipidemias
Hyperlipidemias
Lipid Metabolism
France
Outpatients
Multivariate Analysis
Cross-Sectional Studies
Lipids
Health

Citer dette

Praktiknjo, Michael ; Djayadi, Natalie ; Mohr, Raphael ; Schierwagen, Robert ; Bischoff, Jenny ; Dold, Leona ; Pohlmann, Alessandra ; Schwarze-Zander, Carolynne ; Wasmuth, Jan Christian ; Boesecke, Christoph ; Rockstroh, Jürgen K. ; Trebicka, Jonel. / Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. I: Liver International. 2019 ; Bind 39, Nr. 8. s. 1514-1520.
@article{066301ded56f400490b3fe6a4111dae7,
title = "Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients",
abstract = "Background: Severe hepatic steatosis shows a high prevalence and contributes to morbidity and mortality in human immunodeficiency virus (HIV) infected patients. Known risk factors include obesity, dyslipidaemia and features of metabolic syndrome. Fibroblast growth factor 21 (FGF-21) is involved with hepatic glucose and lipid metabolism. This study aimed to evaluate FGF-21 as a biomarker for severe hepatic steatosis in non-obese HIV-infected patients. Methods: This is a prospective, cross-sectional, monocentric study including HIV-infected out-patients. Hepatic steatosis was measured via controlled attenuation parameter (CAP) using FibroScan 502 touch (ECHOSENS, France). Severe hepatic steatosis was defined at CAP ≥ 253 dB/m. Peripheral blood samples were collected and plasma was analysed for FGF-21. Demographic and clinical characteristics were collected from patient's health records. Results: In total, 73 non-obese HIV-monoinfected patients were included in this study. Prevalence of severe hepatic steatosis was 41{\%}. Patients with severe hepatic steatosis showed significantly higher levels of FGF-21. Univariate analysis revealed FGF-21, BMI, hyperlipidaemia, ALT levels and arterial hypertension as significant, while multivariate analysis showed only FGF-21, arterial hypertension and ALT levels as significant independent risk factors for severe hepatic steatosis. Conclusion: This study presents FGF-21 as an independent and stronger predictor of severe hepatic steatosis than blood lipids in HIV-infected patients. Moreover, arterial hypertension and ALT levels predict severe steatosis even in non-obese HIV-monoinfected patients. Furthermore, this study supports existing metabolic risk factors and expands them to non-obese HIV-infected patients.",
keywords = "BMI, CAP, dyslipidaemia, FGF-21, fibroscan, HIV, hyperlipidaemia, liver, NAFLD, NASH, steatosis",
author = "Michael Praktiknjo and Natalie Djayadi and Raphael Mohr and Robert Schierwagen and Jenny Bischoff and Leona Dold and Alessandra Pohlmann and Carolynne Schwarze-Zander and Wasmuth, {Jan Christian} and Christoph Boesecke and Rockstroh, {J{\"u}rgen K.} and Jonel Trebicka",
year = "2019",
month = "8",
doi = "10.1111/liv.14107",
language = "English",
volume = "39",
pages = "1514--1520",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "8",

}

Praktiknjo, M, Djayadi, N, Mohr, R, Schierwagen, R, Bischoff, J, Dold, L, Pohlmann, A, Schwarze-Zander, C, Wasmuth, JC, Boesecke, C, Rockstroh, JK & Trebicka, J 2019, 'Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients', Liver International, bind 39, nr. 8, s. 1514-1520. https://doi.org/10.1111/liv.14107

Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. / Praktiknjo, Michael; Djayadi, Natalie; Mohr, Raphael; Schierwagen, Robert; Bischoff, Jenny; Dold, Leona; Pohlmann, Alessandra; Schwarze-Zander, Carolynne; Wasmuth, Jan Christian; Boesecke, Christoph; Rockstroh, Jürgen K.; Trebicka, Jonel.

I: Liver International, Bind 39, Nr. 8, 08.2019, s. 1514-1520.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients

AU - Praktiknjo, Michael

AU - Djayadi, Natalie

AU - Mohr, Raphael

AU - Schierwagen, Robert

AU - Bischoff, Jenny

AU - Dold, Leona

AU - Pohlmann, Alessandra

AU - Schwarze-Zander, Carolynne

AU - Wasmuth, Jan Christian

AU - Boesecke, Christoph

AU - Rockstroh, Jürgen K.

AU - Trebicka, Jonel

PY - 2019/8

Y1 - 2019/8

N2 - Background: Severe hepatic steatosis shows a high prevalence and contributes to morbidity and mortality in human immunodeficiency virus (HIV) infected patients. Known risk factors include obesity, dyslipidaemia and features of metabolic syndrome. Fibroblast growth factor 21 (FGF-21) is involved with hepatic glucose and lipid metabolism. This study aimed to evaluate FGF-21 as a biomarker for severe hepatic steatosis in non-obese HIV-infected patients. Methods: This is a prospective, cross-sectional, monocentric study including HIV-infected out-patients. Hepatic steatosis was measured via controlled attenuation parameter (CAP) using FibroScan 502 touch (ECHOSENS, France). Severe hepatic steatosis was defined at CAP ≥ 253 dB/m. Peripheral blood samples were collected and plasma was analysed for FGF-21. Demographic and clinical characteristics were collected from patient's health records. Results: In total, 73 non-obese HIV-monoinfected patients were included in this study. Prevalence of severe hepatic steatosis was 41%. Patients with severe hepatic steatosis showed significantly higher levels of FGF-21. Univariate analysis revealed FGF-21, BMI, hyperlipidaemia, ALT levels and arterial hypertension as significant, while multivariate analysis showed only FGF-21, arterial hypertension and ALT levels as significant independent risk factors for severe hepatic steatosis. Conclusion: This study presents FGF-21 as an independent and stronger predictor of severe hepatic steatosis than blood lipids in HIV-infected patients. Moreover, arterial hypertension and ALT levels predict severe steatosis even in non-obese HIV-monoinfected patients. Furthermore, this study supports existing metabolic risk factors and expands them to non-obese HIV-infected patients.

AB - Background: Severe hepatic steatosis shows a high prevalence and contributes to morbidity and mortality in human immunodeficiency virus (HIV) infected patients. Known risk factors include obesity, dyslipidaemia and features of metabolic syndrome. Fibroblast growth factor 21 (FGF-21) is involved with hepatic glucose and lipid metabolism. This study aimed to evaluate FGF-21 as a biomarker for severe hepatic steatosis in non-obese HIV-infected patients. Methods: This is a prospective, cross-sectional, monocentric study including HIV-infected out-patients. Hepatic steatosis was measured via controlled attenuation parameter (CAP) using FibroScan 502 touch (ECHOSENS, France). Severe hepatic steatosis was defined at CAP ≥ 253 dB/m. Peripheral blood samples were collected and plasma was analysed for FGF-21. Demographic and clinical characteristics were collected from patient's health records. Results: In total, 73 non-obese HIV-monoinfected patients were included in this study. Prevalence of severe hepatic steatosis was 41%. Patients with severe hepatic steatosis showed significantly higher levels of FGF-21. Univariate analysis revealed FGF-21, BMI, hyperlipidaemia, ALT levels and arterial hypertension as significant, while multivariate analysis showed only FGF-21, arterial hypertension and ALT levels as significant independent risk factors for severe hepatic steatosis. Conclusion: This study presents FGF-21 as an independent and stronger predictor of severe hepatic steatosis than blood lipids in HIV-infected patients. Moreover, arterial hypertension and ALT levels predict severe steatosis even in non-obese HIV-monoinfected patients. Furthermore, this study supports existing metabolic risk factors and expands them to non-obese HIV-infected patients.

KW - BMI

KW - CAP

KW - dyslipidaemia

KW - FGF-21

KW - fibroscan

KW - HIV

KW - hyperlipidaemia

KW - liver

KW - NAFLD

KW - NASH

KW - steatosis

U2 - 10.1111/liv.14107

DO - 10.1111/liv.14107

M3 - Journal article

VL - 39

SP - 1514

EP - 1520

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 8

ER -